![](https://endpts.com/wp-content/uploads/2023/08/AP23179572573513-scaled.jpg)
Pascal Soriot, AstraZeneca CEO (Justin Tallis/Press Association via AP Images)
Icosavax buyout caps AstraZeneca’s long search for a vaccine platform
AstraZeneca is gaining a late-stage RSV vaccine candidate as part of its proposed acquisition of Icosavax after the British drugmaker spent two years searching for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.